zole-mi-TRIP-tan 
Absorption: Well absorbed (40%) following oral and intranasal administration.
Distribution: Unknown.
Metabolism/Excretion: Mostly metabolized by the liver; some conversion to metabolites that are more active than zolmitriptan. 8% excreted unchanged in urine.
Half-life: 3 hr (for zolmitriptan and active metabolite).
Contraindicated in:
Use Cautiously in:
CV: MI, angina, chest pain/pressure/tightness/heaviness, hypertension, palpitations.
Derm: sweating, warm/cold sensation.
EENT: throat pain/tightness/pressure.
GI: dry mouth, dyspepsia, dysphagia, nausea.
MS: myalgia, myasthenia.
Neuro: hypesthesia, paresthesia , dizziness, drowsiness, vertigo, weakness.
Misc: pain.
Drug-Drug:
Drug-Natural Products:
Hepatic Impairment
12 yr): Single 2.5 mg initially (maximum single dose = 5 mg); may be repeated after 2 hr (not to exceed 10 mg/24 hr); Concurrent cimetidine therapy — Single dose not to exceed 2.5 mg (not to exceed 5 mg/24 hr).Therapeutic Classification: vascular headache suppressants
Pharmacologic Classification: five ht1 agonists
(Generic available)
NDC Code*